Komori
Pharma Foods International (2929) · RiskFirst stated

No Track Record of New Drug Approvals for ALAgene Technology

First written in FY2019. . Latest entry: FY2019.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Uncertainty over Prolonged or Discontinued Drug Development Pipelines and CommercializationA theme 69 companies write about · 85 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2022: 20 of 40 companies on the "Worse" side.

2 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 69 companies compared. The sentences above are computed from all 69.
Full recordFilings, disclosures and news, newest first
  1. FY2019First statedAnnual report

    「The antibodies developed using the Group’s chicken monoclonal antibody production technology, ALAgene® technology (Aladdin Technology), have not yet been approved as new drugs. If the Group is unable to produce results in new drug development in the future, its business development and financial results may be affected.」

    The Company specifies that no new drug approvals have yet been achieved for antibodies developed using ALAgene technology and identifies the risk of failing to achieve development results in the future.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Pharma Foods International yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
No Track Record of New Drug Approvals for ALAgene Technology | Pharma Foods International Co.,Ltd. (2929) | Komori